Maltodextrin/Ascorbic Acid Wound Dressing Study - Dr. Jorge Puerta, MD



A wound-healing rate in diabetic foot ulcers in response to treatment with maltodextrin/ascorbic acid wound dressing in outpatient diabetic foot unit Caja de Seguro Social Ciudad de Panama. A case series report.



Study completed by Jorge Puerta, MD; Jennifer Garcia, MD; and Horacio Moreno, MD Complejo Hospitalario Dr. Arnulfo Arias Madrid

study objectives

The aim of this study was to describe and demonstrate the effectiveness of a diabetic foot limb preservation treatment protocol utilizing sharp debridement, maltodextrin/ascorbic acid dressing, gauze, and limb offloading.

introduction

- Diabetes affects 194 million individuals worldwide¹
- Foot ulceration is one of most common complications associated with diabetes.¹
 - 15% of diabetic patients experience a foot ulcer
 - 7 to 20% of these patients require eventual amputation
- Treatment of diabetic foot wounds is costly due to prolonged care \$4,595 to \$28,000 per diabetic foot ulcer.¹
 - Costs increase to \$40,000 if amputation is required¹
 - Estimated total cost in Panama: \$288.92 Million²
- A protocol is needed to reduce treatment time and burden on healthcare systems, especially in developing countries

introduction: maltodextrin/ascorbic acid dressing

- Dressing in powder and gel formulation
- Initial studies by Silvetti demonstrated efficacy for treating traumatic wounds, decubitus ulcers, venous leg ulcers, diabetic ulcers, and 2nd degree burns³
 - Reported cessation of pain, control of infection and purulence, granulation tissue formation and re-epithelialization of wound bed³
 - Additional experiments indicated Maltodextrin has inherent antimicrobial properties^{4,5}
- Others report successful treatment of recalcitrant wounds including: peristomal ulcers⁶, diabetic⁷⁻⁹, surgical, and traumatic wounds⁸, and venous ulcers.¹⁰
- Dressing is inexpensive making it an ideal treatment option in developing countries with limited resources. However, research is limited to case studies and small clinical studies.

methods

- Prospective observational case series approved by the Ethics Committee of Panama's Ministry of Health
- Included all patients with Wagner Stage 3 and 4 diabetic foot ulcers between January 2014 March 2015
 25 patient records included (26 wounds)
- Treatment Protocol
 - Sharp debridement as indicated and wound cleaned with saline
 - Maltodextrin/ascorbic acid dressing applied to the wound bed
 - Powder for moist/wet, gel for dry wounds
 - Cotton gauze used as secondary and appropriate offloading applied
 - Patients and care givers trained to change dressings daily
- Wounds were photographed and analyzed with digital planimetry at all follow-up visits.
- Healing trajectories and Modified Kaplan-Meier Survival Curves used to quantify granulation tissue formation and healing of the wound.

Representative Cases



Post transmetatarsal amputation.


Week 0: Initial area: 30.94 cm2 , Granulation tissue: 72%. Week 11: Area 4.52 cm2 (85% closed), Granulation tissue: 100%. Week 16: Healed



Surgical Relief of Abscess.


Week 0: Initial Area: 6.93 cm2, Granulation tissue: 100% Week 3: Area 3.68 cm2 (47% closed), Granulation tissue: 100%. Week 7: Healed

Complete Granulation of Wounds Observed in Study



Complete granulation of all wounds was observed


- 100% Median: 57 days; Range: 0 193 days
- 80% Granulation Median: 19 Days; Range: 0 118
- Non-healing wounds were delayed in granulation tissue formation
- Healed Median: 55.5 days; Range: 0 147 days
- Not Healed Median: 93 days; Range: 43 193 days
- Log Rank Test demonstrates trend towards significance (p=0.094)



Right Dorsum Wound with PVD.

Week 0: Initial Area: 32.45 cm2, Granulation tissue: 58.1%, Week 7: Area 4.52 cm2 (85% closed), Granulation tissue: 100%. Week 14: Healed

Treatment Protocol Promotes Wound Healing



All wounds experienced at least 70% wound closure

- 70% Healing Median: 56 days; Range: 14 144 days
- 100% Healing Median: 103 days; Range: 48 193 days
- Non-healing wounds (n=5) resolved through grafting after 100% granulation and 70% healing
- Wound healing trajectories predict 6-7% weekly healing rates



discussion

A wound treatment protocol utilizing debridement, maltodextrin / ascorbic acid dressing, gauze, and offloading led to rapid wound healing of stage II, III, and IV diabetic foot ulcers.

- 21 of 26 wounds healed
- 5 unhealed wounds achieved 70% size reduction and 100% granulation before resolution with grafting

Rapid formation of granulation tissue and re-epithelialization of the wound bed in treated wounds demonstrates protocol creates ideal conditions for wound healing.

- Multidex demonstrated to establish a moist wound environment conducive to wound healing
- Sharp debridement removed slough and necrotic tissue
- Offloading prevented re-injury of the wound bed during healing

Protocol demonstrates the ability to salvage limbs following diabetic ulceration.

- Successfully healed 10 post transmetatarsal amputation wounds (case 1)
- Potential to save \$20 million in Panama alone by preventing full limb amputation

conclusions

- Rapid wound healing was seen for stage II IV diabetic foot wounds utilizing described treatment protocol.
- The maltodextrin/ascorbic acid dressing established an ideal moist environment ideal for wound healing.
- The protocol is cost effective for developing countries with socialized healthcare systems as the maltodextrin/ascorbic acid is inexpensive.

References

- 1 Frykberg et al. J Foot and Ankle. 2006
- 2 World Bank 2012 http://databank.worldbank.org/data/home.aspx
- 3 Silvetti J Dermatol Surg Oncol. 1981
- 4 Silvetti FASEB 1993 p A1251
- 5 Silvetti Federation Proc 1987 p A3898
- 6 Bonham and Schaffner J WOCN 1999
- 7 Earles and Smiddy J WOCN 2003
- 8 Brunette J WOCN 2012
- 9 Palec J WOCN 2012
- 10 Krotzch et al. Wound Repair Regen 2005
- 11 Robson et al. JAMA Surgery 2000
 * Multidex[®] (DeRoyal Industries. Powell TN) This work has been made possible by an education/research grant from DeRoyal Industries.



for a free sample, visit **MULTIDEXSAMPLES.COM**

restrictions apply. see website



DeRoyal®, DeRoyal logo, Improving Care. Improving Business.®, and Multidex® are registered trademarks of DeRoyal Industries, Inc. © 2016. All Rights Reserved.